Key references: Medication-related osteonecrosis of the jaw: dental considerations

  • Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev 2017;10:CD012432. https://www.ncbi.nlm.nih.gov/pubmed/28983908
  • Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016;375(16):1532-43. https://www.ncbi.nlm.nih.gov/pubmed/27641143
  • Dal Pra KJ, Lemos CA, Okamoto R, Soubhia AM, Pellizzer EP. Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. Int J Oral Maxillofac Surg 2017;46(2):151–6. https://www.ncbi.nlm.nih.gov/pubmed/27876532
  • Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent 2013;61(5):33–8. https://www.ncbi.nlm.nih.gov/pubmed/23928436
  • Enciso R, Keaton J, Saleh N, Ahmadieh A, Clark GT, Sedghizadeh PP. Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Am Dent Assoc 2016;147(7):551–60 e11. https://www.ncbi.nlm.nih.gov/pubmed/27040417
  • Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011;142(11):1243–51. https://www.ncbi.nlm.nih.gov/pubmed/22041409
  • Hutcheson A, Cheng A, Kunchar R, Stein B, Sambrook P, Goss A. A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. J Oral Maxillofac Surg 2014;72(8):1456–62. https://www.ncbi.nlm.nih.gov/pubmed/24793621
  • Jenkins N, Black M, Paul E, Pasco JA, Kotowicz MA, Schneider HG. Age-related reference intervals for bone turnover markers from an Australian reference population. Bone 2013;55(2):271–6. https://www.ncbi.nlm.nih.gov/pubmed/23603243
  • Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30(1):3–23. https://www.ncbi.nlm.nih.gov/pubmed/25414052
  • Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab 2018;103(9):3183-93. https://www.ncbi.nlm.nih.gov/pubmed/29931216
  • Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68(2):243–53. https://www.ncbi.nlm.nih.gov/pubmed/19772941
  • McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, et al. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res 2018;33(8):1397-406. https://www.ncbi.nlm.nih.gov/pubmed/29694685
  • Michelsen J, Wallaschofski H, Friedrich N, Spielhagen C, Rettig R, Ittermann T, et al. Reference intervals for serum concentrations of three bone turnover markers for men and women. Bone 2013;57(2):399–404. https://www.ncbi.nlm.nih.gov/pubmed/24076251
  • Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72(10):1938–56. https://www.ncbi.nlm.nih.gov/pubmed/25234529